The DOI matches its Crossref record.
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
Abstract
Objective: Because treatment with tumor necrosis factor (TNF) antagonists may increase the risk of tuberculosis (TB), and because knowledge of the risk of TB in rheumatoid arthritis (RA) not treated with biologics is scarce and of uncertain generalizability to low‐risk populations, this study sought to determine the risk of TB among Swedish patients with RA. Methods: Using data from Swedish nationwide and population‐based registers and data from an ongoing monitoring program of TNF antagonists, the relative risks of TB in patients with RA (versus the general population) and of TB associated with TNF antagonists (versus RA patients not treated with biologics) were determined by comparing the incidence of hospitalization for TB in 3 RA cohorts and 2 general population cohorts from 1999 to 2001. We also reviewed the characteristics of all reported cases of TB in RA patients treated with TNF antagonists in Sweden and calculated the incidence of TB per type of TNF antagonist between 1999 and 2004. Results: During 1999–2001, RA patients who were not treated with TNF antagonists were at increased risk of TB versus the general population (relative risk 2.0, 95% confidence interval [95% CI] 1.2–3.4). RA patients treated with TNF antagonists had a 4‐fold increased risk of TB (relative risk 4.0, 95% CI 1.3–12) versus RA patients not treated with TNF antagonists. The reported TB cases during 1999–2004 in RA patients exposed to TNF antagonists (9 infliximab, 4 etanercept, 2 both) were predominantly pulmonary. TB occurred up to 3 years following the start of treatment. Conclusion: Irrespective of whether TNF antagonists are administered, Swedish patients with RA are at increased risk of TB. During 1999–2001, TNF antagonists were associated with an increased risk of TB, up to 4‐fold in magnitude. This increased risk may persist over time during treatment and is related to both infliximab and etanercept.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
External review and validation of the Swedish national inpatient register
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.-L., Reuterwall, C., Heurgren, M., & Olausson, P. O. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-450 · Cited by 5,055
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
Listing, J., Gerhold, K., & Zink, A. (2013) · Rheumatology · doi:10.1093/rheumatology/kes305 · Cited by 541
Patterns of nonrandom mating within and across 11 major psychiatric disorders
Nordsletten, A. E., Larsson, H., Crowley, J. J., Almqvist, C., Lichtenstein, P., & Mataix-Cols, D. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.3192 · Cited by 210
Dreyer, N. A., Velentgas, P., Westrich, K., & Dubois, R. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.3.301 · Cited by 107
Lee, C.-H., Jeong, Y.-J., Heo, E. Y., Park, J. S., Lee, J. S., Lee, B. J., Park, Y. S., Song, E. H., Yang, Y. J., Cho, Y. S., et al. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-720 · Cited by 38
New drugs in development for the treatment of endometriosis
Fedele, L., Somigliana, E., Frontino, G., Benaglia, L., & Vigano, P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.8.1187 · Cited by 30
Metadata
- Authors
- Askling, J., Fored, C. M., Brandt, L., Baecklund, E., Bertilsson, L., Cöster, L., Geborek, P., Jacobsson, L. T., Lindblad, S., Lysholm, J., Rantapää‐Dahlqvist, S., Saxne, T., Romanus, V., Klareskog, L., & Feltelius, N.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-06-28
- Volume
- 52
- Issue
- 7
- Pages
- 1986-1992
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2020050449
- Cited by
- 419
- References
- 0
- FWCI
- 13.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
